Hepatitis C Patients Taxing Medical System (Hep C Treatment)

Hepatitis C Patients Taxing Medical System
MedicineNet.com - Jan 27 4:21 AM
Title: Hepatitis C Patients Taxing Medical System Category: Health News Created: 12/31/2005 1:59:00 AM Last Editorial Review: 12/31/2005 1:58:37 AMSave to My Web

Schering-Plough Initiates PEG-INTRON(R) Maintenance Study In Patients Coinfected With Hepatitis C And HIV
Medical News Today - Jan 15 4:17 PM
Schering-Ploughannounced today that it is initiating a large multinational clinical trial toevaluate the use of low-dose PEG-INTRON(R) (peginterferon alfa-2b) maintenancemonotherapy in preventing or delaying hepatitis C disease progression and thuspotentially reducing the occurrence of clinical events such as livertransplantation, liver cancer and death in cirrhotic patients with hepatitis Cwho Save to My Web

Novartis and Idenix seek European approval of telbivudine (LDT600) for the ...
Financial.de - Feb 07 12:56 AM
Basel, February 7, 2006 - Novartis ( News / Kurs / Chart / Board ) and Idenix Pharmaceuticals, Inc. announced today the European submission of telbivudine (LTD600) for approval as a novel treatment for patients affected by chronic hepatitis B (CHB), a potentially fatal disease estimated to affect more than three million people in Europe1 and over 350 million people worldwide.Save to My Web

Schering-Plough Drug Gets Fast Track
AP via Yahoo! Finance - Jan 30 6:44 AM
Drug maker Schering-Plough Corp. said Monday that regulators granted "fast track" status to its experimental hepatitis C treatment.Save to My Web

Peregrine Accelerates Tarvacin HCV Study
AP via Yahoo! Finance - Jan 18 5:28 AM
Biopharmaceutical company Peregrine Pharmaceuticals Inc. said Wednesday that it is accelerating its program to test its cancer drug Tarvacin for the treatment of hepatitis C.Save to My Web